[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"musculoskeletal-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:musculoskeletal-diseases":33},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,70,103,149,203,230,271,296,308,338,359,385,409,437,462,500,527,554,576,609,634,657,694,725,764],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":43,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100053565","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-aoc-1044-also-referred-to-as-delpacibart-zotadirsen-in-participants-with-dmd-with-gene-mutations-amenable-to-exon-44-skipping-100053565",false,"NCT07587242","A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping","SAFARI44","Key Inclusion Criteria:\n\n* Ambulatory males with clinical and genetic diagnosis of DMD\n* Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping\n* 7 to 16 years of age at time of consent\n* TTR and NSAA assessment completed within the protocol specified parameters at Screening\n* On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.\n\nKey Exclusion Criteria:\n\n* Previous treatment cell or gene therapy.\n* Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).\n* Lab values outside of the protocol specified range at Screening\n* If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:\n* Less than 1 month, for growth hormone and\u002For testosterone\n* Less than 6 months for givinostat","MALE","7 Years","16 Years",{"count":22,"type":23},70,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping",[29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Muscular Dystrophies","Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)","Muscular Disorders, Atrophic","Muscular Disease","Musculoskeletal Diseases","Neuromuscular Diseases (NMD)","Nervous System Diseases","Genetic Diseases","X-Linked","Hereditary","Neonatal Disease","Duchene Muscular Dystrophy","Congenital","DMD",[44,45,46,47,48,49,50,51,16,52,53,54,55,56,57,42],"AOC","AOC 1044","AOC 1044-CS3","AOC 1044-CS1","AOC 1044-CS2","EXPLORE44","EXPLORE44-OLE","SAFARI","SAFARI 44","Avidity","Avidity Biosciences","Exon Skipping Therapy","Avidity Biosciences Inc., A Novartis Company","del-zota","NOT_YET_RECRUITING","2026-07-10",{"date":61,"type":62},"2026-07-13","ACTUAL",{"date":64,"type":23},"2026-06",{"date":66,"type":23},"2030-07",{"name":68,"class":69},"Avidity Biosciences, Inc.","INDUSTRY",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":101,"locationsCount":102},"100612219","managed-access-program-for-del-zota-in-participants-with-dmd-mutations-amenable-to-exon-44-skipping-100612219","NCT07250737","Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping","Key Inclusion Criteria\n\nRollover Participants\n\n* Completed Study EXPLORE44-OLE Treatment Period (through W102)\n* No significant tolerability issues with AOC 1044\n\nNew (Non-Rollover) Participants\n\n* Permanently residing in the US and have a US primary health care provider\n* Documented dystrophin gene mutation that is amenable to exon 44 skipping\n* Age 2 or older at the time of consent\n* If previously treated with gene therapy for DMD, treatment and associated immunosuppressive regimen was more than 12 months before consent and in the opinion of the prescriber, participant has had an unsatisfactory treatment response\n\nKey Exclusion Criteria\n\nRollover Participants\n\n• Prescence of any new condition or worsening of existing condition that could affect participant's safety or ability to comply with the program requirements\n\nNew (Non-Rollover) Participants\n\n* Recently treated with or on a clinical study for another investigation drug\n* Serious respiratory or cardiac dysfunction, or nearing end of life\n* Screening laboratory parameters do not meet protocol requirements\n* History of multiple drug allergies or to any component of AOC 1044\n* Participants who discontinued early from the treatment period of EXPLORE44 or EXPLORE44-OLE","2 Years","EXPANDED_ACCESS","The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.",[31,81,33,82,35,83,84,29,85],"Muscular Diseases","Neuromuscular Diseases","Genetic Diseases, Inborn","Genetic Diseases, X-Linked","Muscular Dystrophy, Duchenne",[53,54,45,47,48,49,50,87,88,42,89,90,91,92,93,94,95,96],"Del-zota","delpacibart zotadirsen","exon skipping therapy","dystrophin","managed access","expanded access","pre-approval access","compassionate use","MAP","EAP","AVAILABLE","2026-06-26",{"date":100,"type":62},"2026-06-29",{"name":68,"class":69},14,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":24,"phases":115,"briefSummary":117,"conditions":118,"keywords":126,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":148},"100407038","randomized-comparison-of-partial-wrist-fusion-with-or-without-triquetral-excision-parte-100407038","NCT04580225","Randomized Comparison of PARtial Wrist Fusion With or Without Triquetral Excision (PARTE)","PARTE","Inclusion Criteria:\n\n* Participant has a stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) wrist and is a surgical candidate for the included surgical interventions\n\nExclusion Criteria:\n\n* Participant has been diagnosed with other forms of wrist arthritis other than SLAC or SNAC\n* Participant has significant arthritis of the ipsilateral hand\u002Ffinger joint(s), major joint trauma, previous major wrist surgery, infection or neuromuscular pathology affecting the function of the ipsilateral upper extremity or ability to make a fist\n* Participant has a physical or mental health condition preventing completion of consent or questionnaires\n* Participant does not speak\u002Fread\u002Funderstand English\n* Participant has no fixed address or means of contact\n* Participant is unwilling to complete necessary follow-ups\n* Surgeon concludes that eligible salvage techniques are not appropriate at the time of surgery (based on injury characteristics or concomitant wrist pathology)","ALL","18 Years","75 Years",{"count":114,"type":23},170,[116],"NA","This randomized clinical trial (RCT) aims to compare clinical and radiographic outcomes of different partial wrist fusion techniques in participants with post-traumatic wrist arthritis. Participants with stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) who meet the eligibility criteria will be randomly assigned to one of two parallel groups: Group A (partial wrist arthrodesis without triquetral excision i.e. four-corner arthrodesis), or Group B (partial wrist arthrodesis with triquetral excision i.e. three-corner or capitolunate arthrodesis with triquetral excision). The results of this study will provide evidence to guide surgeons in determining the ideal wrist fusion technique in the management of patients with post-traumatic wrist arthritis requiring surgery.",[119,120,121,122,123,124,33,125],"Wrist Arthritis","Wrist Arthropathy","Scapholunate Advanced Collapse","Scaphoid Nonunion","Post-traumatic; Arthrosis","Arthritis","Joint Diseases",[127,128,129,130,131,132,133,134,135,136],"Post-traumatic wrist arthritis","Partial wrist fusions","Scapholunate advanced collapse","SLAC wrist","Scaphoid nonunion advanced collapse","SNAC wrist","Four-corner fusion","Bicolumnar wrist fusion","Three-corner fusion","Capitolunate fusion","RECRUITING","2026-06-19",{"date":140,"type":62},"2026-06-24",{"date":142,"type":62},"2021-01-07",{"date":144,"type":23},"2027-04",{"name":146,"class":147},"University of Alberta","OTHER",5,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":156,"sex":110,"minAge":111,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":160,"conditions":161,"keywords":176,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",true,{"count":158,"type":23},1000000,"OBSERVATIONAL","The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[162,163,164,165,166,167,168,33,169,170,171,172,173,174,175],"Aging","Aging Well","All-Cause Mortality","Mortality","Metabolic Syndrome","Cardiovascular Diseases","Cognitive Dysfunction","Neoplasms","Frailty","Activities of Daily Living","Health-Related Quality of Life","Disability Physical","Neuro-Degenerative Disease","Dementia",[177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192],"Longevity","Cardiopulmonary Exercise Testing","Body Composition","Preventive Medicine","Surrogate Endpoint Validation","Mortality Prediction","Functional Decline","Healthspan","Life Expectancy","Biological Aging","Preventive Screening","Longitudinal Cohort","Biomarker Validation","Human Performance","Population Health","Centenarian","2026-06-09",{"date":195,"type":62},"2026-06-11",{"date":197,"type":62},"2025-02-09",{"date":199,"type":23},"2099-12-31",{"name":201,"class":69},"Longevity Metrics, Inc.",1,{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":110,"minAge":210,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":202},"100637790","translation-cultural-adaptation-and-standardization-of-e-nmq-100637790","NCT07626619","Translation, Cultural Adaptation, and Standardization of E-NMQ","Translation, Cultural Adaptation, and Standardization of the Extended Version of the Nordic Musculoskeletal Questionnaire (E-NMQ) for the Urdu-Speaking Population","Inclusion Criteria:\n\n* Age between 18 and 45 years.\n\n  * Both male and females\n  * Able to speak and read Urdu language Individuals with a condition affecting the musculoskeletal system\n  * Age matched healthy individual recruited will be either the attendants\u002Ffamily members accompanying patients in Jinnah Hospital or employees of Riphah International University.\n\nExclusion Criteria:\n\n* Pregnant females, inflammation, local infection, fracture, suspected tumor, Recent surgery\n\n  * Unwilling patients\n  * Cognitive impairment \\& speech impairment\n  * Any neurological diseases (reflex changes \\& loss of sensation)","20 Years","45 Years",{"count":213,"type":23},110,"The primary objective of this study is to translate the Nordic Musculoskeletal (E-NMQ) Questionnaire Modified Version into Urdu following international guidelines. Presently, there exists no validated tool to comprehensively measure symptoms such as pain, stiffness and weakness in Urdu-speaking patients in Pakistan. Specifically, the widely used E-NMQ, having these three vital categories, has yet to be translated and validated for Urdu-speaking individuals with musculoskeletal disease (MSD).",[33],[217,218,219,220],"Cultural Adaptation","Musculoskeletal Disorders","Reliability","Validity","2026-06-01",{"date":223,"type":62},"2026-06-04",{"date":225,"type":23},"2026-06-18",{"date":227,"type":23},"2026-11-06",{"name":229,"class":147},"Riphah International University",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":156,"sex":110,"minAge":111,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":242,"conditions":243,"keywords":255,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":202},"100600783","hyperthermia-in-patients-with-chronic-primary-pain---effects-on-thermoregulation-somatosensory-system-and-movement-evoked-pain-100600783","NCT07101978","Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain","Hyperthermia in Healthy and Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System, Movement Evoked Pain (HYPPRI-1)","HYPPRI-1","Inclusion Criteria:\n\npatients:\n\n* Confirmed diagnosis of widespread pain (ICD-11 MG30.01)\n* Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) scale ≥ 5 or WPI) ≥ 3 and SS ≥ 9,\n* Pain \\>= 3 month and VAS \\>= 4,0\n* Body - infrared-A-Bulb Distance \\\u003C 38cm (overweight participants)\n* Signed declaration of consent\n\nhealthy:\n\n* No chronic illnesses\n* No acute infections\n* No regular medication: To avoid interactions\n* BMI ≤ 40kg\u002Fcm2\n* Mental health: No psychiatric diagnoses or psychotropic medication in your medical history\n\nExclusion Criteria:\n\n* Participation in other clinical studies\n* Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women)\n* Acute and \u002F or feverish microbial infections\n* Participants with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases\n* participants who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha\u002Fbeta-A(nta)gonists due to a disease from the group described above\n* participants with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders\n* pregnancy or breastfeeding (for women)\n* Intake of medication within 6 weeks that inhibits the reuptake of the neurotransmitter serotonin or binds to receptors of this neurotransmitter group","70 Years",{"count":240,"type":23},60,[116],"This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.",[244,245,246,32,247,33,248,249,250,251,252,253,254],"Hyperthermia","Chronic Primary Pain","Widespread Pain","Rheumatic Diseases","Neuromuscular Disease","Fibromyalgia","Circadian Rhythm","Body Temperature Changes","Somatosensory Function","Quantitative Sensory Testing","Healthy",[256,257,258,259,260,261],"hyperthermia","widespread pain","chronic primary pain","circadian body temperature","quantitative sensory testing","healthy","2026-05-29",{"date":264,"type":62},"2026-06-02",{"date":266,"type":23},"2026-08-01",{"date":268,"type":23},"2028-12-31",{"name":270,"class":147},"Bern University of Applied Sciences",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":156,"sex":110,"minAge":279,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":24,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":202},"100459773","mode-of-exercise-and-bone-biomarkers-in-older-veterans-100459773","NCT05266976","Mode of Exercise and Bone Biomarkers in Older Veterans","Anabolic Versus Catabolic Skeletal Effects of Endurance or Resistance Exercise in Older Veterans","MOVE","Inclusion Criteria:\n\n* Healthy older (60+ y) Veteran women and men in the Denver Metro Area\n* Normally active (e.g., recreational cycling or walking exercise)\n\nExclusion Criteria:\n\n* Impaired renal function, defined as an eGRF of \\\u003C60 mL\u002Fmin\u002F1.73m2\n* Hepatobiliary disease, defined as liver function tests (AST, ALT) \\>1.5 times the upper limit of normal\n* Thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) \\\u003C0.5 or \\>5.0 mU\u002FL\n* Serum Ca \\\u003C8.5 or \\>10.3 mg\u002FdL\n* Serum 25(OH)D \\\u003C20 ng\u002FmL\n* Uncontrolled hypertension, defined as resting systolic blood pressure (BP) \\>150 mmHg or diastolic BP \\>90 mmHg;\n* History of type 1 or type 2 diabetes\n* Cardiovascular disease, defined as subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test (GXT). Volunteers who have a positive GXT can be re-considered after follow-up evaluation, which must include diagnostic testing (e.g., stress echocardiogram or thallium stress test) with interpretation by a cardiologist\n* Anemia, defined as a serum hemoglobin \\\u003C12.1 g\u002FdL for women and \\\u003C14.3 g\u002FdL for men\n* Fracture in the past 6 months\n* Current diagnosis or symptoms of COVID-19\n\nIn the event of abnormal BP, live function, TSH, 25(OH)D, or hemoglobin values, volunteers can be reassessed, including after appropriate follow-up evaluation and treatment by a primary care provider. Those who have experienced symptoms of COVID-19 or have been formally diagnosed will be allowed to participate once symptoms have resolved and they are approved to return to exercise by their primary care provider.","60 Years",{"count":281,"type":23},120,[116],"Adults are often encouraged to exercise to maintain or improve bone health. However, there is evidence that exercise does not always lead to increases in bone mass, and exercise could lead to bone loss under certain conditions. Endurance exercise can increase bone resorption following an exercise bout, which may explain why bone does not always favorably adapt to exercise, but it is unclear if this also happens with resistance exercise. Further, it is not known how exercise training influences blood markers of bone resorption for either endurance or resistance exercise. The purpose of this study is to determine 1) if resistance exercise causes a similar increase in bone resorption as endurance exercise; and 2) if exercise training influences the increase in bone resorption following exercise for both endurance and resistance exercise.",[162,33,285],"Osteoporosis","2026-05-19",{"date":288,"type":62},"2026-05-22",{"date":290,"type":62},"2022-07-06",{"date":292,"type":23},"2027-06-30",{"name":294,"class":295},"VA Office of Research and Development","FED",{"id":297,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":298,"targetDuration":4,"studyType":24,"phases":299,"briefSummary":27,"conditions":300,"keywords":301,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":307,"locationsCount":4},"100638788",{"count":22,"type":23},[26],[29,30,31,32,33,34,35,36,37,38,39,40,41,42],[44,45,46,47,48,49,50,51,16,52,53,54,55,56,57,42],"2026-05-08",{"date":304,"type":62},"2026-05-14",{"date":64,"type":23},{"date":66,"type":23},{"name":68,"class":69},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":110,"minAge":315,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":319,"conditions":320,"keywords":323,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":202},"100621209","development-of-multidimensional-screening-tool-for-wmsds-100621209","NCT07367646","Development of Multidimensional Screening Tool for WMSDs","Development and Validation of a Multidimensional Screening Tool for Work-Related Musculoskeletal Disorders: A COSMIN-Guided Psychometric Study","Inclusion Criteria:\n\n* Current regular employees working at the study site.\n* Adults aged 19 years or older who understand the study purpose and procedures and voluntarily agree to participate in writing.\n* Participants capable of reading, understanding, and self-responding to the questionnaire.\n* Individuals with musculoskeletal symptoms according to NIOSH standards: symptoms lasting more than one week OR recurring at least once a month in the past 12 months (symptoms include pain, aching, stiffness, burning sensation, tingling, or numbness).\n\nExclusion Criteria:\n\n* Individuals with cognitive or mental impairments that make it difficult to understand the study or complete the survey.\n* Individuals suspected of having a medical emergency or severe disease requiring immediate medical attention.\n* Individuals deemed unsuitable for participation by the researcher.","19 Years","65 Years",{"count":318,"type":23},250,"The purpose of this study is to develop a multidimensional screening tool for Work-Related Musculoskeletal Disorders (WMSDs) and to evaluate its psychometric properties. The study involves a cross-sectional survey of approximately 250 workers in the bio-pharmaceutical industry to assess the tool's structural validity, internal consistency, construct validity, and measurement invariance following COSMIN guidelines.",[321,33,322],"Work-Related Musculoskeletal Disorders","Occupational Diseases",[324,325,326,327,328],"WMSDs","Musculoskeletal Pain","Screening Tool","Psychometrics","Occupational Health","2026-04-22",{"date":331,"type":62},"2026-04-24",{"date":333,"type":23},"2026-06-20",{"date":335,"type":23},"2026-12-31",{"name":337,"class":147},"Sahmyook University",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":110,"minAge":344,"maxAge":279,"enrollmentInfo":345,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":202},"100599782","musculoskeletal-disorders-of-postgraduate-dentistry-students-and-specialist-dentists-100599782","NCT07088965","Musculoskeletal Disorders of Postgraduate Dentistry Students and Specialist Dentists","Inclusion Criteria\n\n* Being between 25 and 60 years of age\n* Having a stable professional career\n\nExclusion Criteria\n\n* Having physical conditions such as rheumatoid arthritis or fibromyalgia\n* Being retired\n* Being an undergraduate student\n* Having a history of any major accident, trauma, or medical condition causing permanent musculoskeletal disability","25 Years",{"count":346,"type":23},90,"This study aimed to assess the prevalence of MSDs and the level of ergonomics knowledge among dentists who are specializing in different branches or have completed specialist training.",[33,349],"Work-related Injury","2026-03-27",{"date":352,"type":62},"2026-04-01",{"date":354,"type":62},"2025-05-15",{"date":356,"type":23},"2026-05-15",{"name":358,"class":147},"Abant Izzet Baysal University",{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":366,"targetDuration":4,"studyType":24,"phases":367,"briefSummary":368,"conditions":369,"keywords":374,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":202},"100534824","comparison-of-ultrasound-guided-injection-with-median-nerve-decompression-surgery-in-carpal-tunnel-syndrome-100534824","NCT06243848","Comparison of Ultrasound-Guided Injection With Median Nerve Decompression Surgery in Carpal Tunnel Syndrome","Comparison of Ultrasound-Guided Injection With Traditional Median Nerve Decompression Surgery in Patients With Carpal Tunnel Syndrome: Randomized Controlled Study","Inclusion Criteria:\n\n* The presence of symptoms such as nocturnal, posture-related, or movement-related paresthesias, along with possible pain, in the area supplied by the median nerve in the hand, lasting for more than 3 months.\n* Confirmation of mild, moderate or severe CTS through electrophysiological testing.\n* Numbness and loss of sensation in the hand's regions innervated by the median nerve, as well as weakness in the thenar muscles innervated by the median nerve.\n* Positive results on either the Phalen test and\u002For Tinel sign.\n\nExclusion Criteria:\n\n* Individuals who may exhibit symptoms mimicking carpal tunnel syndrome, such as cervical radiculopathy, polyneuropathy, brachial plexopathy, or thoracic outlet syndrome.\n* Patients who have received a previous injection into the carpal tunnel within the past 6 months.\n* Thenar muscle atrophy.\n* A history of prior carpal tunnel surgery.\n* Regular usage of systemic nonsteroidal anti-inflammatory drugs and corticosteroids.\n* Pregnancy\n* Patients diagnosed with rheumatoid arthritis, systemic lupus erythematosus, gout, systemic sclerosis, dermatomyositis, or polymyositis.\n* Malignancy.\n* Active infections",{"count":240,"type":23},[116],"The aim of this study is to compare ultrasound-guided perineural injection of the median nerve with classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.",[33,370,371,372,373],"Median Nerve Disease","Carpal Tunnel Syndrome","Ultrasound-Guided Injection","Surgery",[371,372,375],"Median Nerve Decompression","2026-03-10",{"date":378,"type":62},"2026-03-12",{"date":380,"type":62},"2024-01-25",{"date":382,"type":23},"2026-05-24",{"name":384,"class":147},"Afyonkarahisar Health Sciences University",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":156,"sex":110,"minAge":210,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":202},"100496326","the-relationship-between-ultrasonographic-findings-and-sleep-quality-in-carpal-tunnel-syndrome-100496326","NCT05742776","The Relationship Between Ultrasonographic Findings and Sleep Quality in Carpal Tunnel Syndrome","The Relationship Between Ultrasonographic Findings and Sleep Quality in Patients With Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Patients diagnosed with CTS according to the criteria of the American Academy of Neurology\n\nExclusion Criteria:\n\n* Patients with radiculopathy, brachial plexopathy, thoracic outlet syndrome and traumatic nerve injury that may affect the median nerve\n* History of Carpal tunnel surgery\n* Pregnancy\n* Malignancy\n* Thyroid diseases\n* Amyloidosis\n* Systemic lupus erythematosus, Rheumatoid arthritis, Systemic sclerosis, Gout, Dermatomyositis, Polymyositis\n* Obstructive sleep apnea","80 Years",{"count":281,"type":23},"The aim of our study is to determine the relationship between disease severity and sleep quality in CTS patients and to compare the findings with healthy controls.",[33,370,371,396,397],"Ultrasound","Sleep Quality",[371,399,400],"Ultrasonographic evaluation","Pittsburgh Sleep Quality Index","2026-03-06",{"date":403,"type":62},"2026-03-09",{"date":405,"type":62},"2023-02-23",{"date":407,"type":23},"2026-07-01",{"name":384,"class":147},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":156,"sex":110,"minAge":417,"maxAge":316,"enrollmentInfo":418,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":420,"conditions":421,"keywords":425,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100627166","physical-activity-levels-and-musculoskeletal-health-among-health-science-academicians-at-istanbul-aydin-university-100627166","NCT07445100","Physical Activity Levels and Musculoskeletal Health Among Health Science Academicians at Istanbul Aydin University","PHYSICAL ACTIVITY LEVELS AND THEIR ASSOCIATION WITH POSTURE, SLEEP QUALITY, DEPRESSION, AND MUSCULOSKELETAL PROBLEMS AMONG HEALTH SCIENCE ACADEMICIANS AT ISTANBUL AYDIN UNIVERSITY","PA-ACAD-IAU","Inclusion Criteria:\n\n* Academicians working in the Faculty of Health Sciences at Istanbul Aydın University\n* Aged between 23 and 65 years\n* At least 1 year of academic experience\n* Voluntary agreement to participate and signed informed consent\n\nExclusion Criteria:\n\n* Diagnosis of severe psychiatric disorders (e.g., schizophrenia)\n* Pregnancy\n* Use of antipsychotic medication\n* History of recent trauma or surgical operation within the last year\n* Severe musculoskeletal disorders requiring medical or surgical treatment (e.g., advanced scoliosis or kyphosis)","23 Years",{"count":419,"type":23},73,"This study aims to investigate the relationship between physical activity levels and posture, sleep quality, depression, and musculoskeletal system problems among academic staff working in the health sciences field at Istanbul Aydın University.\n\nModern technological developments and sedentary work patterns have significantly reduced daily physical activity levels. Academic personnel often spend long hours sitting, preparing lectures, conducting research, and using computers, which may negatively affect posture and increase the risk of musculoskeletal pain. Reduced physical activity has also been associated with poor sleep quality and increased depressive symptoms.\n\nThis cross-sectional study will include academic staff aged 23-65 years working in the Faculty of Health Sciences. Participation will be voluntary. Data will be collected using a sociodemographic information form and validated assessment tools, including the International Physical Activity Questionnaire-Short Form (IPAQ), New York Posture Rating Chart, Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and the Nordic Musculoskeletal Questionnaire.\n\nThe primary objective is to evaluate whether physical activity levels are associated with posture, sleep quality, depression levels, and musculoskeletal complaints. The findings are expected to contribute to the development of preventive strategies aimed at improving occupational health, well-being, and quality of life among academic personnel.",[33,422,423,424],"Depression","Sleep Wake Disorders","Posture",[426,328,325,397,427],"Academic Personnel","Cross-Sectional Study","2026-02-25",{"date":430,"type":62},"2026-03-03",{"date":432,"type":23},"2026-03",{"date":434,"type":23},"2026-05",{"name":436,"class":147},"Istanbul Aydın University",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":202},"100403652","multi-vendor-multi-site-novel-accelerated-mri-relaxometry-100403652","NCT04536103","Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry","MVMS_MRI","Inclusion Criteria:\n\nGroup 1\n\n1\\. Age \\> 18\n\nGroup 2\n\n1\\. Age 18-50\n\nGroup 3\n\n1. Age 18-50\n2. Sustain an acute full ACL tear in one knee; the contralateral knee uninjured\n3. Undergo ACL reconstructions and standard rehabilitation\n\nGroup 4\n\n1\\. Age 18-50\n\nExclusion Criteria:\n\nGroup 1\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n\nGroup 2\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. History of osteoarthritis and inflammatory arthritis\n4. Previous injury and\u002For surgery on either knee\n\nGroup 3\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. Inability to undergo standard pre- and post-injury\u002Foperative rehabilitation\n\nGroup 4\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. History of osteoarthritis and inflammatory arthritis\n4. Previous injury and\u002For surgery on either knee","50 Years",{"count":446,"type":23},88,"Currently the diagnosis of OA is based on radiographs and clinical findings, which is limited to detecting late-stage disease. There is a pressing, unmet clinical need for robust assessment of early changes in cartilage health. Towards this goal, extensive efforts are ongoing to develop quantitative MRI for cartilage matrix analysis. MR T1ρ and T2 relaxation times have shown to be promising imaging biomarkers for early cartilage degeneration and prediction of disease progression. However, many challenges remain to clinically applying these techniques, including lack of standardized acquisition and quantification methods, and long acquisition times. The study aims to develop novel, fast and reproducible MR T1ρ and T2 relaxation time imaging methods on MR systems from multiple vendors and establish a platform for standardization and cross validation of these measures as a tool for clinical trials using such techniques. Following method validation, patients at risk for osteoarthritis will be tested.",[449,33,125,450,451,452],"Bone Diseases, Infectious","Osteoarthritis","ACL Tear","Cartilage Degeneration","2026-02-24",{"date":455,"type":62},"2026-02-27",{"date":457,"type":62},"2022-04-01",{"date":459,"type":23},"2026-12-28",{"name":461,"class":147},"Xiaojuan Li",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":470,"minAge":111,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":24,"phases":472,"briefSummary":473,"conditions":474,"keywords":479,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":4},"100624462","multicomponent-care-for-aromatase-inhibitor-related-musculoskeletal-symptoms-100624462","NCT07409948","Multicomponent Care for Aromatase Inhibitor-Related Musculoskeletal Symptoms","Clinical Effectiveness and Implementation Outcomes of a Multicomponent Intervention for Aromatase Inhibitor-Associated Musculoskeletal Symptoms: A Hybrid Type 1 Randomized Controlled Trial","AIMSS-CARE","Inclusion Criteria:\n\n1. Pathologically confirmed hormone receptor-positive (HR+) breast cancer.\n2. Aged 18 years or older.\n3. Currently receiving aromatase inhibitor therapy (e.g., anastrozole, letrozole, or exemestane) for at least 2 months.\n4. Experiencing aromatase inhibitor-induced musculoskeletal symptoms, defined as a worst joint pain score ≥ 2\u002F10 on the Brief Pain Inventory (BPI) during the past 7 days.\n5. Capable of understanding the study and willing to sign informed consent.\n\nExclusion Criteria:\n\n1. History of fracture or major surgery within the past 6 months.\n2. Patients diagnosed with arthritis (e.g., rheumatoid arthritis).\n3. Patients diagnosed with osteoporosis according to WHO criteria (T-score -2.5).\n4. Recurrent or metastatic breast cancer, or receipt of chemotherapy or radiotherapy during the study period.\n5. Presence of other primary malignancies.\n6. Patients with severe heart, brain, liver, or kidney dysfunction, or infectious diseases.\n7. Patients with severe mental, cognitive, or behavioral disorders that hinder understanding or participation in the study.","FEMALE",{"count":446,"type":23},[116],"Breast cancer patients who receive endocrine therapy particularly aromatase inhibitors often experience aromatase inhibitors associated symptoms (AIMSS) such as joint and muscle pain along with stiffness and fatigue that can disrupt with daily activities and lead some patients to stop treatment early. A structured intervention program named AIMSS-CARE (Aromatase Inhibitor-associated Musculoskeletal Symptoms-Comprehensive Adapted Rehabilitation Evaluation) developed in China that combines exercise, education, symptom monitoring, and follow-up has been shown to reduce these symptoms and improve treatment adherence.\n\nThis study will adapt this program for use in Ethiopia while testing its effectiveness to enhance pain management, treatment adherence and quality of life among Ethiopian breast cancer patients receiving endocrine therapy. The study will be conducted at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia.\n\nEighty-eight patients will be randomly assigned to either the adapted intervention program or usual care. The research will also examine the feasibility and acceptability of the intervention to patients and healthcare providers, and what factors influence its successful implementation. Results will help determine whether this program can be used more widely in Ethiopia and other African cancer centers.",[475,325,476,33,477,478],"Breast Neoplasms","Arthralgia","Pain","Fatigue Syndrome, Chronic",[480,481,482,483,484,485,486,487,488,489,490],"Breast neoplasms","Aromatase inhibitors","endocrine therapy","Randomized controlled trial","pain","quality of life","fatigue","treatment adherence","musculoskeletal symptoms","symptom monitoring","exercise and rehabilitation","2026-02-07",{"date":493,"type":62},"2026-02-13",{"date":495,"type":23},"2026-03-15",{"date":497,"type":23},"2026-11",{"name":499,"class":147},"Addis Ababa University",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":4,"enrollmentInfo":507,"targetDuration":509,"studyType":159,"phases":4,"briefSummary":510,"conditions":511,"keywords":512,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":202},"100504025","the-national-musculoskeletal-audit-and-research-database-100504025","NCT05842915","The National Musculoskeletal Audit and Research Database","Developing and Testing a Musculoskeletal National Audit in Community\u002FPrimary Care","Inclusion Criteria:\n\n(MSK Services)\n\n* MSK service seeing adult (+18 years) set in community care\n* MSK service with at least 10 WTE HCPs\n* System in place for digital collection of PROM\u002FPREM data\n\n(FCP Services)\n\n* FCP service seeing adult (+18 years) in primary care\n* FCP service with at least 1 WTE FCP seeing MSK patients\n* Use of EMIS or SYSTMONE\n* Able to implement Midlands FCP template\n* System in place for digital collection of PROM\u002FPREM data\n\n(For patients)\n\n* +18 years\n* Active phone number or verified email address to participate in the patient questionnaire\n* Able to provide informed consent\n\nExclusion Criteria:\n\n(MSK Services)\n\n\\* Secondary care MSK services\n\n(For patients)\n\n* Has declined for data to be part of research as part of consent process\n* Unable to complete surveys due to health issues including severe or terminal illness, severe learning difficulties or psychological disorders",{"count":508,"type":23},22000,"12 Months","Developing and testing a musculoskeletal national audit in community\u002Fprimary care",[33],[513,514,515,516,517],"Primary Care","Community","Benchmarking","Audit","Quality Improvement","2026-02-04",{"date":520,"type":62},"2026-02-05",{"date":522,"type":62},"2024-05-07",{"date":524,"type":23},"2028-06-07",{"name":526,"class":147},"Keele University",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":238,"enrollmentInfo":534,"targetDuration":4,"studyType":24,"phases":536,"briefSummary":537,"conditions":538,"keywords":541,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":202},"100423945","the-effects-of-afo-heel-height-and-stiffness-on-gait-100423945","NCT04800484","The Effects of AFO Heel Height and Stiffness on Gait","AFOHeel","GROUP 1 Patient Inclusion criteria\n\n* Ages: 18-70\n* Daily AFO use to address unilateral, below knee functional deficits that result from limb injury or musculoskeletal disease (e.g. fracture, muscle and\u002For nerve injury, ankle arthritis)\n* Greater than 2 weeks using their current AFO\n* Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)\n* Ability to walk at a slow to moderate pace\n* AFO fits into traditional footwear\n* Able to read and write in English and provide written informed consent\n\nGROUP 1 Patient Exclusion criteria\n\n* Pain \\> 6\u002F10 while walking during testing or an increase in pain during testing of \\> 2\u002F10.\n* Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity).\n* Disorder or disease that affects peripheral nerve function (e.g. diabetes, Charcot Marie Tooth).\n* Limited contralateral lower limb function due to injury or neurological\u002Fmusculoskeletal disorder.\n* Use of a hinged\u002Farticulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist\u002Fstop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.\n* Use of an AFO that crosses the knee (Knee brace)\n* Insufficient space in shoe to accommodate the tallest heel wedge and their AFO\n* Visual or hearing impairments that limit walking ability or could limit the ability to comply with instructions given during testing\n* Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study.\n* Body Mass index \\> 40.\n\nGROUP 2 Patient Inclusion Criteria\n\n* Ages: 18-70\n* Daily AFO use to address below knee functional deficits that result from disease involving the peripheral nervous system (e.g. Charcot Marie Tooth, Multiple Sclerosis, diabetes)\n* Greater than 2 weeks using their current AFO (unilateral or bilateral)\n* Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)\n* AFO fits into traditional footwear\n* Ability to walk at a slow to moderate pace\n* Able to read and write in English and provide written informed consent\n\nGROUP 2 Patient Exclusion Criteria\n\n* Pain \\> 6\u002F10 while walking or an increase in pain during testing of \\> 2\u002F10\n* Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity)\n* Limited function due to limb injury (e.g. fracture, muscle and\u002For nerve injury)\n* Use of a hinged\u002Farticulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist\u002Fstop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.\n* Use of an AFO that crosses the knee (Knee brace)\n* Insufficient space in shoe to accommodate the tallest heel wedge and their AFO\n* Visual or hearing impairment that limit walking ability or limit the ability to comply with instructions given during testing\n* Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study\n* Body Mass index \\> 40.",{"count":535,"type":23},40,[116],"The proposed study evaluates the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited. In this study, heel cushions with different height and stiffness's (4 conditions) will be placed in participants shoes and they will walk at controlled and self-selected speeds. Participants will also walk with their AFO as configured prior to enrollment, and with no AFO if possible. The proposed study will provide evidence that can be used by clinicians and researchers to align braces that most effectively improve function during every-day walking.",[539,33,540],"Musculoskeletal Injury","Peripheral Nervous System Diseases",[542,543,544],"Gait Analysis","Ankle Foot Orthosis","Biomechanics","2025-12-29",{"date":547,"type":62},"2025-12-31",{"date":549,"type":62},"2019-11-07",{"date":551,"type":23},"2027-01-01",{"name":553,"class":147},"University of Iowa",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":4,"enrollmentInfo":561,"targetDuration":563,"studyType":159,"phases":4,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":202},"100551508","eular-impact-of-rheumatic-and-musculoskeletal-diseases-survey-100551508","NCT06461000","EULAR Impact of Rheumatic and Musculoskeletal Diseases Survey","ImpactSurvey","Inclusion Criteria:\n\n* 18-year-old at time of baseline survey\n* Living in a EULAR country at time of baseline survey\n* Diagnosed with at least one RMD\n* Valid personal e-mail address\n* Being able to use an internet website\n\nExclusion Criteria:\n\n* none",{"count":562,"type":23},1000,"5 Years","The EULAR Impact of RMDs Survey collects first-hand information about the impact of rheumatic and musculoskeletal diseases (RMDs) among patients across and beyond Europe. Through periodic questionnaires, patients will provide information about their healthcare situation, and how the disease affects their social and occupational lives. This data will be an important resource for researchers, healthcare professionals, and patients alike, providing valuable insights into the burden of disease and helping improve the overall care for people living with these conditions.",[566,33],"Rheumatologic Disease","2025-11-18",{"date":569,"type":62},"2025-11-21",{"date":571,"type":62},"2025-06-12",{"date":573,"type":23},"2029-06-12",{"name":575,"class":147},"European Alliance of Associations in Rheumatology",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":238,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":585,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":202},"100611832","shoulder-health-after-rehabilitation-and-performance-training-100611832","NCT07245706","Shoulder Health After Rehabilitation and Performance Training","Ensuring Shoulder Health as a Key Factor for Long Term Health and Functioning of Manual Wheelchair Users","SHARP","Inclusion Criteria:\n\n* Persons with a paraplegia below T2\n* Manual wheelchair user\n* Age 18 - 70 years\n* At discharge from initial rehabilitation\n\nExclusion Criteria:\n\n* Trauma or surgery of the shoulder with medical indication for immobilization of more than four weeks\n* Constant use of power assistance for the wheelchair\n* Any surgical implants that exclude the participant for MRI assessments of the shoulder\n* Inability to follow the study instructions, e.g., mental health problems, language problems, dementia, claustrophobia (for MRI) etc.\n* Persons with congenital conditions leading to SCI, SCI in the context of palliative care, neurodegenerative disorders, and Guillain-Barré syndrome\n* Pregnancy",{"count":535,"type":23},[116],"The goal of this study is to investigate the impact of a home-based shoulder strength training on the overall shoulder health in manual wheelchair users, and if the timepoint of such a training makes a difference. The study is focusing on persons with a spinal cord injury in the thoracic or lumbar region of the spine, that have only recently been injured and will soon be discharged from primary rehabilitation.\n\nThe shoulder training will take place either 3 or 12 months after discharge from primary rehabilitation and will be carried out twice a week for 12 weeks.\n\nThere are six measurements occurring every three months, which leads to an overall duration of 15 months. The measurements consist of:\n\n* Questionnaires about independence in daily life, participation, quality of life and physical activity\n* Assessment of shoulder strength, range of motion and function\n* Measurement of the daily wheelchair use during one week via sensors that are fixed to the wheelchair and wrist\n* one further questionnaire at the end of the measurement week about the occurrence of shoulder pain\n\nAdditionally, on four of the six measurement timepoints, a magnet resonance image (MRI) of the shoulder will be taken to assess the shoulder status (pathology, muscle volume and quality).\n\nThough all these measurements the researchers can additionally assess the load of daily life on the shoulders, and how well this matches the preparation during the primary rehabilitation.",[588,35,33,589],"Spinal Cord Injury","Injury",[591,592,593,594,595,596,597,598],"Shoulder","Wheelchair","Training","Activity of Daily Life","Load","Capacity","Functioning","Monitoring","2025-11-17",{"date":601,"type":62},"2025-11-24",{"date":603,"type":23},"2025-12",{"date":605,"type":23},"2029-12",{"name":607,"class":608},"Swiss Paraplegic Research, Nottwil","NETWORK",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":616,"targetDuration":4,"studyType":24,"phases":618,"briefSummary":619,"conditions":620,"keywords":623,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":202},"100611538","sakurabead-used-as-resorbable-embolic-for-plantar-fascia-embolization-100611538","NCT07241884","SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization","SURE-PF","Inclusion Criteria:\n\n1. Patient is able and willing to provide written informed consent, and\n2. Age 18 to 75 years (inclusive), and\n3. Clinical diagnosis of PF with proximal plantar fascia thickness greater than 4mm and areas of hypoechogenicity.\n\nExclusion Criteria:\n\n1. Acute internal derangement of the foot including acute meniscal, ligament or bone injury, or\n2. Sensory or motor neuropathy of the feet, or\n3. Heel pain caused by stress fractures, nerve entrapment, or inflammatory conditions such as arthritis, gout, or bursitis, or\n4. Prior surgical repair or plantar fascia rupture in the involved foot, or\n5. Local infection in either foot, or\n6. Contraindication to MRI, or\n7. Active pregnancy as demonstrated by urine or serum β-hCG or lactating female\n8. Unable to provide informed consent or comply with the conditions of the study, or\n9. At the discretion of the Principal Investigator",{"count":617,"type":23},45,[116],"This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from pain secondary to plantar fasciitis.",[621,622,33],"Plantar Fascitis","Heel Pain",[624,625,626,622],"Fasciitis","Musculoskeletal disease","Foot disease",{"date":569,"type":62},{"date":629,"type":62},"2025-10-20",{"date":631,"type":23},"2027-03",{"name":633,"class":69},"CrannMed",{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":156,"sex":470,"minAge":111,"maxAge":641,"enrollmentInfo":642,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":644,"conditions":645,"keywords":648,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":655,"locationsCount":202},"100496059","sarcopenia-and-related-factors-in-lipedema-100496059","NCT05739279","Sarcopenia and Related Factors in Lipedema","Evaluation of Sarcopenia and Associated Factors in Patients with Lipedema","Inclusion Criteria:\n\n* between the ages of 18-85\n* with a diagnosis of lipoedema\n* who agreed to participate in the study\n* having a sociocultural level suitable for participation in the study\n* healthy volunteers in a similar age group for the control group\n\nExclusion Criteria:\n\n* with chronic venous insufficiency and\u002For lymphedema\n* with Parkinson's disease, previous stroke, cerebellar diseases, multiple sclerosis, major depression, neuromuscular diseases, history of major orthopedic surgery, severe hip\u002Fknee osteoarthritis, rheumatological diseases, malignancies, advanced heart\u002Fliver\u002Frenal failure, visual impairment, and vestibular diseases, and those who use any assistive device to walk\n* who are illiterate and have cognitive impairment that will prevent them from giving written consent will not be included in the study","85 Years",{"count":643,"type":23},102,"Lipedema is a common disease of subcutaneous adipose tissue. The most common complaint of patients with swelling in the affected extremity is pain. In addition, patients with lipedema may experience conditions that can greatly affect the health and quality of life of the individual, such as loss of muscle strength and exercise capacity, and deterioration in activity levels of daily living. It is still unknown whether the decrease in muscle strength in patients with lipedema is part of this condition or whether decreased activity levels lead to decreased muscle strength.\n\nSarcopenia is an important health problem characterized by age-related loss of muscle mass and muscle function. The relationship between muscle weakness and sarcopenia in patients with lipedema has not been investigated before. Early recognition of possible sarcopenia and functional limitations in these patients may be important to increase the ability of patients to participate in physical activity as part of their conservative management.\n\nThere is no study in the literature investigating sarcopenia in patients with a diagnosis of lipedema. The aim of this study is to evaluate patients with a diagnosis of lipedema in terms of sarcopenia. In addition, the relationship between sarcopenia and age, body mass index, exercise frequency, lipedema type, and stage will be investigated in patients diagnosed with lipedema.",[646,647,33],"Lipedema","Sarcopenia",[646,647,33],"2025-03-09",{"date":651,"type":62},"2025-03-12",{"date":653,"type":62},"2023-01-01",{"date":603,"type":23},{"name":656,"class":147},"Dokuz Eylul University",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":667,"conditions":668,"keywords":681,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":692,"locationsCount":202},"100486132","gene-expression-profiles-in-spinal-tuberculosis-100486132","NCT05610098","Gene Expression Profiles in Spinal Tuberculosis.","Comparing Gene Expression Profiles of Adults With Isolated Spinal TB to Disseminated Spinal TB Identified by 18FDG-PET\u002FCT at Time of Diagnosis, 6-and 12-months Follow-up","SpinalTBX","Inclusion Criteria\n\n1. Participant has completed the written informed consent process prior to undergoing any clinical evaluations and willing to undergo HIV testing\n2. TB spine based on clinical and radiological criteria\n3. Age 18 or older with a body weight of at least 40 kg body weight\n4. Able and willing to return to follow-up\n5. Willing to have samples, including DNA including RNA extraction, stored\n6. Willing to consistently practice a highly reliable method of pregnancy prevention\n\nExclusion Criteria\n\n1. Pregnancy or active desire to become pregnant within the next 6 months.\n2. Uncontrolled diabetes (HbA1c ≥ 6.5% \u002F random glucose concentration ≥11.1 mmol\u002Fl, fasting plasma glucose ≥ 7.0 mmol\u002Fl)\n3. Alcohol and substance abuse which might interfere with medication adherence during the trial\n4. Positive SARS-CoV-2 PCR in the past 4 weeks\n5. Suspicion of malignancy on MRI or known malignancy\n6. Suspicion of inflammatory disease and other rheumatological conditions\n7. Any person for whom the physician feels this study is not appropriate",{"count":666,"type":23},100,"Tuberculosis (TB) is one of the top ten causes of death worldwide with approximately 10 million cases globally and 1.2 million deaths. Sub-Saharan Africa carries the highest burden of TB. South Africa has one of the highest HIV and TB rates worldwide with an HIV prevalence rate in adults of 19% and a TB case notification rate of 615\u002F100,000 in 2019. Over many years, focus has been paid to pulmonary TB and extrapulmonary TB (EPTB) has received only little attention even though it accounts for almost a quatre of all TB cases. The diagnosis of EPTB remains challenging simply because sample collection requires invasive procedures in the absence of a blood-based diagnostic test. Spinal TB (spondylitis or spondylodiscitis caused by Mycobacterium tuberculosis) - often known as Pott's disease - accounts for up to 10% of EPTB and affects young children, people with HIV-coinfection and elderly, and often leads to lifelong debilitating disease due to devastating deformation of the spine and compression of neural structures. Little is known with regards to the extent of disease and isolated TB spine as well as a disseminated form of TB spine have been described. The latter presents with a spinal manifestation plus disseminations to other organs such as the lungs, pleura, lymph nodes, the GIT or urinary tract or even the brain.\n\nIn the Spinal TB X cohort, the investigators aim to describe the clinical phenotype of spinal TB using whole body PET\u002FCT and identify a specific gene expression profile for the different stages of dissemination and compare findings to previously described signatures for latent and active pulmonary TB. A blood-based test for spinal TB would lead to earlier diagnosis and treatment in all settings globally and improve treatment outcome of this devastating disease.",[669,670,671,672,673,449,33,674,675,676,677,678,679,680],"Tuberculosis, Spinal","Tuberculosis, Osteoarticular","Tuberculosis","Mycobacterium Infections","Infections","Spinal Disease","Spondylitis","Spondylitis; Tuberculosis (Manifestation)","Spondylodiscitis","Positron-Emission Tomography","Diagnostic Imaging","Diagnostic Techniques and Procedures",[682,683,684,685],"Spinal TB","tuberculous spondylodiscitis","FDG-PET\u002FCT","POC","2024-08-22",{"date":688,"type":62},"2024-08-23",{"date":690,"type":62},"2022-10-25",{"date":335,"type":23},{"name":693,"class":147},"University of Cape Town",{"id":695,"slug":696,"hasResults":12,"nctId":697,"briefTitle":698,"officialTitle":699,"acronym":700,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":4,"enrollmentInfo":702,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":704,"conditions":705,"keywords":708,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":715,"lastUpdatePostDateStruct":716,"startDateStruct":718,"completionDateStruct":720,"leadSponsor":722,"locationsCount":724},"100555752","the-bern-rehab-registry-100555752","NCT06516172","The Bern Rehab Registry","The Bern Rehab Registry - a Prospective Cohort Study in Patients With Chronic Non-communicable Diseases Participating in a Comprehensive Rehabilitation Programme","BernRehabReg","Inclusion Criteria:\n\n* Patients aged 18 years and older with a chronic non-communicable disease\n* Signed general informed consent\n* Referral to a comprehensive disease-specific rehabilitation program\n\nExclusion Criteria:\n\n* Refuted or missing general informed consent for further use of health-related data and samples.",{"count":703,"type":23},30000,"This study examines the health outcomes of patients with long-term illnesses such as cancer, heart, lung, or musculoskeletal diseases who participate in a rehabilitation programme. The programme may involve staying in a facility (inpatient), visiting a facility (outpatient), home-based care supported by digital health tools (telerehabilitation), or a combination of facility- and home-based options.\n\nThe key health outcomes being measured include physical fitness and strength, body composition (like body fat and muscle mass), specific risk factors related to the diseases, and patients' self-reported health and experience outcomes, such as feelings of anxiety, depression, fatigue, overall quality of life, and satisfaction with the rehabilitation programme.\n\nThese measurements provide important information about the patients' lung, heart, and muscle health, as well as their mental well-being. They also help to predict the likelihood of further health complications, the chance of needing to be hospitalized again, and overall quality of life. This information is useful for improving the quality of care, tailoring future provision of rehabilitation services and long-term care for patients with chronic conditions.\n\nAdditionally, the study will provide insights into how new technologies like telerehabilitation are implemented, including how well they are adopted, followed, and accepted by patients.",[706,167,33,707],"Cancer","Pulmonary Disease",[709,710,711,712,713,714],"Rehabilitation","Prevention","Physical Function","Mental Function","Participation","Disabilities","2024-08-15",{"date":717,"type":62},"2024-08-19",{"date":719,"type":62},"2020-12-01",{"date":721,"type":23},"2030-12",{"name":723,"class":147},"Insel Gruppe AG, University Hospital Bern",2,{"id":726,"slug":727,"hasResults":12,"nctId":728,"briefTitle":729,"officialTitle":730,"acronym":4,"eligibilityCriteria":731,"healthyVolunteers":156,"sex":110,"minAge":111,"maxAge":4,"enrollmentInfo":732,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":734,"conditions":735,"keywords":749,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":755,"lastUpdatePostDateStruct":756,"startDateStruct":758,"completionDateStruct":760,"leadSponsor":762,"locationsCount":4},"100557135","digital-diagnostics-and-intervention-services-for-parkinsons-disease-100557135","NCT06534177","Digital Diagnostics and Intervention Services for Parkinson's Disease","Development of Digital Diagnostics and Intervention Services for Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank Criteria) or other appropriate condition specific scale \\[stroke, multiple sclerosis, arthritis or osteoporosis\\]\n* Able to self-report history of daily gait freezing and\u002For festination for people with PD or gait and\u002For transfers affected by condition\n* Able to walk unsupported or using an aid for at least 5 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands Healthy participants \\[Phase 1,2,3\\]\n* With no long-term conditions affecting movement\n* Able to walk unsupported or using an aid for at least 3 minutes and satisfactory completion of the Canadian PARQ and\n* if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands\n\nExclusion Criteria:\n\n* Participants with long-term conditions affecting movement\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implant that may interfere with the measurement system Healthy participants\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implants that may interfere with the measurement system",{"count":733,"type":23},80,"People with Parkinson's have infrequent clinical consultation (once every 12-18 months) and limited rehabilitation.\n\nAssessment play an important role in these consultations to help clinicians understand patients' health status and disease progression necessary to adjust treatment plans. The current way of measuring is the UPDRS which needs a clinician to do this and takes 30 minutes. There is a strong need for more frequent and accurate Parkinson's assessments in the clinic and at home to detect changes early and then give appropriate support and drug and physiotherapy quickly. There is a need to develop good home digital physiotherapy tools to increase the amount of therapy. Here the investigators are testing new digital technologies to do these assessments in the home and clinic and a new digital physiotherapy device in the home. The investigators aim to conduct a clinical study with 50 people with Parkinson's (50 from UK) with the UPDRS, (a rating scale that is commonly used in clinical settings to evaluate the progression of Parkinson's disease) and 30 healthy adults. The investigators will develop and investigate if two new digital devices, one the MachineMD that measures eye movement and one the gaitQ that measures gait can be used instead of the MDS-UPDRS (motor) using digital gait and ophthalmic features in the clinic setting. The investigators will investigate the effect of a physiotherapy gait intervention gaitQ Tempo in the home context for two weeks and of doing the gait measure at home. The investigators will determine the potential of the gaitQ intervention to improve key gait metrics in order to collect clinical evidence and of using the gaitQ as a cuing system over a 2-week period on gait and other movement measures in the home and community",[736,737,35,125,33,738,739,740,741,174,742,743,744,745,746,747,124,285,748],"Brain Diseases","Central Nervous System Diseases","Parkinson Disease","Basal Ganglia Diseases","Movement Disorders","Synucleinopathies","Demyelinating Disease, Autoimmune, CNS","Demyelinating Disease","Autoimmune Diseases","Immune System Diseases","Bone Diseases, Metabolic","Bone Diseases","Multiple Sclerosis",[750,751,752,753,754],"parkinson's disease","osteoarthritis","stroke","MS","osteoporosis","2024-08-06",{"date":757,"type":62},"2024-08-09",{"date":759,"type":23},"2024-10-15",{"date":761,"type":23},"2026-03-01",{"name":763,"class":147},"University of Exeter",{"id":765,"slug":766,"hasResults":12,"nctId":767,"briefTitle":768,"officialTitle":769,"acronym":4,"eligibilityCriteria":770,"healthyVolunteers":12,"sex":110,"minAge":111,"maxAge":771,"enrollmentInfo":772,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":774,"conditions":775,"keywords":776,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":778,"lastUpdatePostDateStruct":779,"startDateStruct":781,"completionDateStruct":783,"leadSponsor":785,"locationsCount":202},"100541159","clinical-validation-of-musculoskeletal-icf-core-set-in-primary-care-physiotherapy-100541159","NCT06326229","Clinical Validation of Musculoskeletal ICF Core Set in Primary Care Physiotherapy","Clinical Validation of the Content of an ICF Core Set for the Management of Musculoskeletal Conditions in Primary Care Physiotherapy Services","Inclusion Criteria:\n\n* 18 years of age or older\n* Patients diagnosed with a musculoskeletal condition by a general practitioner\n* Patients with adequate knowledge of the Spanish language\n\nExclusion Criteria:\n\n* Patients referred for a non-musculoskeletal problem\n* Patients referred from hospital services","99 Years",{"count":773,"type":23},385,"The aim of this observational study is to validate the content of a tailored ICF core set for the management of musculoskeletal conditions in primary care physiotherapy services.\n\nThe main question it aims to answer is:\n\n\\- Are the ICF entities included in the ICF Core Set under evaluation useful from a clinical point of view?\n\nParticipants will evaluate the relevance of each ICF entity included in the ICF core set according to their musculoskeletal condition.",[33],[777],"Musculoskeletal Diseases, ICF, Primary Health Care, Physical Therapy Modalities","2024-06-25",{"date":780,"type":62},"2024-06-27",{"date":782,"type":62},"2024-06-17",{"date":784,"type":23},"2025-09-26",{"name":786,"class":147},"University of Valladolid"]